Stablepharma secures Innovate UK grant, bridge funding round to launch

Stablepharma Ltd awarded a second Innovate UK Grant, in partnership with the University Hospital of Southampton NHS Foundation Trust, as they commence a bridge-funding round in Q4 2023.
This joint Innovate UK grant will contribute to the progress of Stablepharma’s SPVX02, a fridge-free vaccine for the prevention of Tetanus diphtheria, validating its safety and efficacy through first-in-human clinical trials.

“This is a great endorsement of the work our R&D team are doing to achieve Stablepharma’s vision of making fridge-free vaccines a reality’, said Özgür Tuncer, CEO & Executive Director. ‘As we know, there are vast challenges within the global cold chain which hinder the efficient distribution and storage of vaccine. ‘Tetanus, for example, remains an important public health problem where immunisation coverage is low and several countries in the world still do not provide tetanus booster shots to protect their populations throughout life”, added Özgür.

Professor Saul Faust OBE, of NHS University Hospital of Southampton, will lead and conduct the delivery of the clinical trials for the SPVX02 (Td) vaccine. ‘’Project success has the tremendous potential for eradicating vaccine wastage and moving away from the need for the cold-chain - this will have huge benefits that will ultimately provide greater safety and effectiveness for vaccines’’, said Professor Faust.

Stablepharma’s technology platform, StablevaX™ converts existing approved vaccines to fridge-free status. By creating pre-dosed and thermostable vaccines, it will ensure safe, efficient and waste-free delivery without the need for the often-unreliable cold chain.

“As we progress towards first-in-human clinical trials for SPVX02, we are delighted to welcome Dr Karen O’Hanlon to the Stablepharma team as Head of Clinical Development’, said Özgür. ‘Karen, having been VP of Clinical Operations for Alan Boyd Consultants, our long-term regulatory advisor, will lead the clinical trials with Professor Faust”.

Stablepharma Ltd recently announced that it will commence a bridge-funding round in Q4 2023 to progress the launch of SPVX02 (Td), a second fridge-free vaccine SPVX06 (Tetanus mono) and their mRNA research programme. “Although these are challenging times economically, we continue to see an increased level of interest from investors, shareholders, partners and vaccine manufacturers in our fridge-free vaccine technology, StablevaX™”, said Özgür Tuncer.

Stablepharma’s R&D team have identified up to 60 vaccine candidates that could be suitable for StablevaX™ technology. By eliminating the need for cold-chain transportation, distribution and storage, StablevaX™ will dramatically increase the availability of existing and new vaccines to patient populations globally’.

Stablepharma actively partners with global vaccine manufacturers, academic institutions and NGOs. Stablepharma has in place a manufacturing agreement with Thermo Fisher Scientific [NYSE:TMO]  for the GMP manufacture of SPVX02. There are currently no fridge-free vaccine solutions on the marketplace.


More news and updates 

ImmuONE is celebrating triple triumph at the inspiring herts awards 2024

We’re proud to announce that ImmuONE took home the prestigious award for ‘Business of the Year – North Herts’, which was awarded to us for consistent growth, robust financial performance, and unwavering commitment to staff and innovation. From the pool of winners, there was also a special recognition category which honoured ImmuONE with the ‘Inspiring Business of the Year’ award for making the biggest innovation in Hertfordshire.

Cryoport systems officially launches global supply chain hub in Stevenage

Cryoport, Inc a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art Global Supply Chain Hub in Stevenage, U.K.

Microbiotica to present positive update on manufacturing progress of its live biotherapeutic products

Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Milner Institute celebrates success of 2024 Pitch Day and therapeutics symposium

The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.

Moa harvests global deal for new herbicide

Moa Technology has signed a major research and commercial agreement with Australian ag giant Nufarm. The deal will see Moa receiving receive upfront payments, milestone development payments and royalties in return for Nufarm gaining exclusive access to a product in one of Moa's breakthrough novel mode of action areas.

Myricx Bio announces £90 million Series A financing to advance its novel NMTi-ADC therapeutics into clinical development

£90 million ($114 million) series A co-led by new leading life science investors Novo Holdings and Abingworth; additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners.

NCIMB Ltd kicks off innovative enzyme technology development project

Aberdeen-based biotechnology company NCIMB has kicked-off a new research project to demonstrate novel enzyme technology with an exciting array of potential applications in the pharmaceutical, food & drink and environmental sectors.

Promising results from cardiac fibrosis studies with MRX1

Ananda Developments PLC, a clinical-stage life sciences company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is delighted to share promising results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).

Valneva Scotland appoints science communications consultancy, Perceptive Communicators

Glasgow-based specialist communications consultancy, Perceptive Communicators, has announced its appointment to provide strategic communications services for Valneva Scotland.

Coulter Partners places Head of Sales North America at Pelago Bioscience

Coulter Partners recently partnered with Pelago Bioscience and is pleased to announce the placement of Brian Jarecki, PhD as Head of Sales North America.


More within